Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) – Analysts at Brookline Capital Markets upped their FY2026 earnings estimates for Adial Pharmaceuticals in a report released on Monday, May 11th. Brookline Capital Markets analyst K. Dolliver now expects that the company will earn ($7.09) per share for the year, up from their prior forecast of ($7.34). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($7.34) per share.
A number of other analysts have also issued reports on ADIL. UBS Group set a $8.00 price target on shares of Adial Pharmaceuticals in a research report on Wednesday, February 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research report on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $22.75.
Adial Pharmaceuticals Price Performance
NASDAQ ADIL opened at $1.38 on Wednesday. The company has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $4.59. The firm has a market capitalization of $1.97 million, a price-to-earnings ratio of -0.09 and a beta of 1.27. Adial Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $18.90.
Adial Pharmaceuticals (NASDAQ:ADIL – Get Free Report) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.73) by $1.25.
Hedge Funds Weigh In On Adial Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ADIL. Jane Street Group LLC raised its position in Adial Pharmaceuticals by 887.3% during the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock valued at $27,000 after acquiring an additional 109,500 shares in the last quarter. Citadel Advisors LLC bought a new position in Adial Pharmaceuticals during the third quarter valued at approximately $51,000. Finally, Armistice Capital LLC bought a new position in Adial Pharmaceuticals during the fourth quarter valued at approximately $562,000. Institutional investors own 16.41% of the company’s stock.
Adial Pharmaceuticals Company Profile
Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.
The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.
See Also
- Five stocks we like better than Adial Pharmaceuticals
- A Real Biggie Deal: Wendy’s Serves Up a Juicy Buyout Arbitrage
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
Receive News & Ratings for Adial Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adial Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
